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Both linear and conformational determinants of hepatitis C virus (HCV) are believed to be involved in viral neutralization.
After immortalization of B cells from HCV chronically infected patients with Epstein-Barr virus, we obtained two polyclonal
lymphoblastoid cell lines (LCL) secreting human monoclonal antibodies (HMabs). One clone was derived from a patient
infected with a genotype 4 isolate while the second was isolated from a genotype 1b-infected patient. Immunoprecipitation
studies, Western blot, and immunofluorescence analysis, peptide scanning, and ELISA studies indicated that the HMabs (1)
recognized conformation-dependent determinant(s), (2) were capable of recognizing genotype 1a and 1b derived antigens,
and (3) were able to precipitate noncovalently associated E1E2 complexes believed to exist on the surface of virion particles.
The HMab derived from the genotype 4-infected patient was in addition shown to neutralize the in vitro binding of
recombinant E2 protein onto susceptible cells suggesting a potential for in vivo neutralization. These data indicate that
anti-E2 antibodies directed at conserved conformational-dependent determinant(s) exist in chronic HCV infection. © 1998
Academic Press
INTRODUCTION
Hepatitis C virus (HCV) is the principal causative agent
for non-A, non-B hepatitis. The prevalence of HCV infec-
tion in the blood donor population has been estimated to
range from 0.4 to 2% (Choo et al., 1989). Acute HCV
infection leads, in more than 70% of the patients, to the
development of chronic hepatitis, which can evolve to-
ward cirrhosis and hepatocellular carcinoma (Saito et al.,
1990). HCV is an enveloped positive-stranded RNA virus
which is classified in the Flaviviridae family (Francki et
al., 1991, Miller and Purcell, 1990). It contains a genome
of about 9500 nts encoding a polyprotein of 3010–3033
amino acids. Processing of the polyprotein by host and
viral proteases results in the production of structural and
nonstructural (NS) proteins (Rice, 1996). Structural pro-
teins include a nucleocapsid and two putative virion
envelope glycoproteins E1 and E2 (Miyamura and Mat-
suura, 1993). Nonstructural proteins include NS2–NS5
antigens.
In some individuals, acute infection successfully re-
solves, indicating that HCV can be controlled by the host
immune system. The mechanisms by which the host
overcomes HCV infection remain unknown. Previous re-
ports strongly suggest that humans and chimpanzees
can generate virus-neutralizing antibodies (Choo et al.,
1994, Farci et al., 1994, 1996, Shimizu et al., 1994). Suc-
cessful in vivo protection of chimpanzees from primary
infection by an homologous HCV isolate has been
achieved following immunization with recombinant E1
and E2 proteins (Choo et al., 1994). In that study, only
those chimpanzees showing high anti-E2 antibody titers
were protected. While neutralizing antigenic domains
were not identified, it was postulated that conformation
of the immunogens was critical for the induction of neu-
tralizing antibodies.
As there is to date no efficient in vitro replication
system to grow the virus and develop neutralization as-
says, alternative assays to assess the biological function
of anti-E1/E2 antibodies are being actively searched for.
Prevention of viral attachment onto presumed suscepti-
ble cells has been described in preliminary studies
(Shimizu et al., 1994, Zibert et al., 1995). More recently, an
‘‘in vitro’’ neutralization of binding (NOB) assay has been
developed that is exploiting the specific binding of a
highly purified E2 protein onto susceptible target cells
(Rosa et al., 1996). This assay allows the quantitative
evaluation of NOB antibodies that are capable of neu-
tralizing the binding of E2 onto such cells. Using this
system, Rosa et al. (1996) have shown that only those
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chimpanzees immunized with E1 and E2 proteins that
developed high anti-NOB titers were protected against
challenged infection, suggesting that NOB activity could
be an indication for ‘‘in vivo’’ neutralization of viral infec-
tion. In HIV infection, a similar model has recently shown
that affinity of antibody binding to envelope glycoprotein
oligomers was a good predictor for virus neutralization
(Fouts et al., 1997). Another way to assess the biological
activity of anti-E1 and/or anti-E2 antibodies consists of
testing the ability of such antibodies to recognize native
structures believed to exist on the surface of virions. In
vitro studies have shown that E1 and E2 interact to form
noncovalently linked complexes (Ralston et al., 1993;
Deleersnyder et al., 1997). Such complexes have been
proposed to represent functional subunits of HCV virions
(Ralston et al., 1993; Dubuisson et al., 1994; Dubuisson
and Rice, 1996; Deleersnyder et al., 1997).
In the present study, we have used a conformation-
dependent antibody screening assay specific for the
HCV E2 glycoprotein with the goal of generating human
monoclonal antibody (HMAb)-producing cell lines. We
successfully derived two HCV-producing clones from two
chronically infected patients and analyzed the immune
reactivity of the produced HMAbs in terms of epitope
mapping, capacity to recognize noncovalently linked
E1E2 complexes, and detection of NOB activity.
RESULTS
Patients’ screening and generation of human
monoclonal antibody producing B cells (LCLs)
Table 1 summarizes characteristics of the two patients
and of the two lymphoid B-cell lines producing HMAbs,
designated 503 and 108. Analysis of culture superna-
tants from the two clones revealed that both clones
secreted IgG1 l only. LCLs produced 2–5 mg of Ab/ml of
conventional culture medium. Genotyping of Patient 1
and 2 infecting viruses was at time of peripheral blood
mononuclear cell (PBMC) immortalization and on two
times within the past 2 years prior to the immortalization
using two different assays. Both assays gave concordant
results and indicated that Patient 1 was infected by a
genotype 4 isolate while Patient 2 was infected by a
genotype 1b isolate. As commercially available HCV
genotyping assays may be lacking specificity and to
exclude the possibility of dual infection, we further con-
firmed the above results by the analysis of PCR-derived
sequences mapping within the 59 noncoding region of
the HCV genome. Nucleotide sequences derived from
cloned quasispecies was compared to published data-
bases (Bukh et al., 1992), and the results confirmed those
obtained with the commercial genotyping assays, i.e.,
that both patients were infected with a single viral type
(data not shown). Figure 1 illustrates the staining of
SVE2-infected CV-1 cells observed in the IFA using the
patients’ sera (A and B) or the purified monoclonal anti-
bodies (C and D). The reactivity was localized in the
cytoplasm with a predominant perinuclear distribution.
Immunological characteristics of the HMAbs
Western blot analysis, immunofluorescence, and
epitope mapping studies. Different approaches were
used to characterize the immune reactivity of the pro-
duced antibodies. Western blot analysis using denatur-
ing conditions and protein preparations containing sub-
type 1a- or 1b-derived E2 proteins (Nakano et al., 1997)
were performed using the original patients’ sera, super-
natants from the LCLs, and purified antibodies. While
sera of both HCV-infected patients reacted with the E2
1a- and 1b-derived proteins, none of the culture super-
natants or purified HMAbs gave a positive signal even
when tested at concentrations as high as 10 mg/ml (data
not shown). No reactivity could be observed either when
culture supernatants or purified antibodies were tested
in a peptide scanning ELISA using a panel of synthetic
peptides covering a E2 1a sequence (data not shown).
As the above observations suggested that the recog-
nized determinants may be of nonlinear nature, immune
reactivity of the different samples was analyzed in IF
assays. Cells were transfected with a panoply of plas-
mids expressing different domains of E2 (see Fig. 2) to
try and identify restricted determinant sequences. Re-
sults of the IF studies are summarized in Table 2. Serum
of Patient 1 recognized multiple determinants mapping
within the sequences expressed from various E2-ex-
pressing plasmids. In contrast, the HMAb 503 derived
from this patient recognized only the near full-length
expressed form of E2 (encoded by plasmid pCIE2t) but
none of the smaller expressed forms of the antigen. For
Patient 2, the serum as well as the derived 108 antibody
reacted only against the largest expressed form of E2.
TABLE 1
Characteristics of Patients and Derived Human Anti-E2
Monoclonal Antibodies
Patients Genotypea
Viral loadb
Eq/ml 3 105
Histological
diagnosis HMAbs Isotypec
1 4 5.2 Mild chronic
hepatitis
503 IgG1l
2 1b 21.8 Cirrhosis 108 IgG1l
a Analysis were made with samples derived from the day of patients’
EBV-PBMC transformation as well as from two different time points
during a two year follow-up. Results at the different time points and
between the different assays were concordant.
b Quantified in serum with the Quantiplex bDNA assay (Quantiplex
HCV RNA Assay, Chiron Diagnostics, Emeryville).
c Supernatants from each clone were tested by IFA on CV-1 infected
cells with the recombinant SVE2 virus and staining was revealed using
specific secondary antibodies for human IgM, IgG, IgA, IgG1-4 sub-
classes.
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Thus using this approach, we were unable to identify
restricted determinant sequences recognized by either
of the purified antibodies.
All the above experiments involved a subtype 1a-de-
rived antigen. We evaluated the capacity of the purified
monoclonal antibodies to, in addition, recognize a sub-
type 1b-derived E2 as a way to evaluate their cross-
reactive potential. Reactivity of the HMAbs was tested by
immunoprecipitation using cells infected with a recom-
binant Sindbis virus, Sinrep/HCV-BK1–1207, expressing
such an antigen. Both antibodies were capable of rec-
ognizing the antigen as shown by the observation of
strong, specific signals (data not shown).
Taken together with the above results, these data
suggest that the HMAbs are capable of recognizing
determinants specific of at least two different E2 subtype
(1a and 1b)-derived antigens. In addition, they strongly
suggest that the antibodies are likely to recognize con-
formation-dependent determinants.
Immunoprecipitation studies. The absence of reactivity
of the HMAbs in Western blotting and by IFA on LTK cells
transfected by a panel of vectors expressing different
truncated parts of E2 suggests that the Abs recognize
conformation-dependent epitope(s). We therefore further
evaluated the recognition of E2 by the HMAbs in pulse
chase experiments. In addition, as previous reports have
suggested that E1 and E2 interact to form complexes
which have been proposed to be functional subunits
incorporated in the virion particles (Deleersnyder et al.,
1997), we also evaluated the ability of the HMAbs to
recognize such complexes. These E1E2 complexes are
noncovalently associated or stabilized by intramolecular
disulfide bonds forming E1E2 aggregates. Covalently as-
sociated E1E2 complexes have also been reported that
are not believed to be part of the functional subunits of
the viral particles (Grakaoui et al., 1993; Ralston et al.,
1993; Dubuisson et al., 1994).
The HMAbs recognize an early folded domain of E2.
Immunoprecipitations were performed to characterize
the proteins recognized by these HMAbs (Fig. 3). Murin
anti-E2 MAbs directed at conformation-independent
(MAb A11) or conformation-dependent (MAb H2) epi-
topes were used for comparison (Dubuisson et al., 1994;
Deleersnyder et al., 1997). Under reducing conditions,
HMAbs 108 and 503 did not precipitate the E2 protein
during the pulse, but after 30 min of chase, a band
corresponding to E2 started to be detected with an in-
creased intensity after 60 min (Fig. 3, reducing HMAbs
108 and 503). This is in contrast with results obtained
using the murin MAb A11 directed at a conformation-
serum from a patient with chronic hepatitis unrelated to HCV. An
additional negative control (F) included CV-1 cells transfected with a
SVE1 recombinant virus (expressing E1) and stained with the HMAb
503 or 108 (result is shown for HMAb 503 only).
FIG. 1. Indirect immunofluorescence analysis. CV-1 cells were in-
fected with the SVE2 recombinant virus as previously described
(Fournillier-Jacob et al., 1996) and immunofluorescence analysis per-
formed using patients’s sera (1:20 dilution) or supernatants from the
HMAbs producing cell lines. Staining was performed using goat-anti
human IgG immune serum coupled with fluoresceine. (A) serum from
Patient 1; (B) serum from Patient 2; (C) HMAb 503; (D) HMAb 108; (E)
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independent epitope (Fig. 3, reducing MAb A11). As pre-
viously observed with this latter antibody, heterogeneous
E2-related products were detected during the pulse
probably as a consequence of a translational pause
during the synthesis of the NS2 region in the E2-NS2
precursor (Dubuisson and Rice, 1996). For the MAb A11,
the intensity of the E2-NS2 precursor precipitated was
very high after 30 min of chase and decreased with time,
whereas it was low and rather constant for the E2-NS2
protein precipitated by the HMAbs 108 and 503, indicat-
ing that E2 was mainly precipitated by the Abs after its
cleavage from the E2-NS2 precursor. Comparison with
immunoprecipitation performed with the conformation-
dependent MAb H2 indicated a greater delay in the
detection of E2 (Fig. 3, reducing, MAb H2). These obser-
vations indicate that indeed the HMAbs recognize a
conformation-dependent domain of E2 which appears
early during the maturation process of the E2 protein.
The estimated half-time of epitope formation for both
HMAbs was around 15 min (data not shown).
The HMAbs can precipitate noncovalent E1E2 com-
plexes. Additional pulse chase experiments were per-
formed under nonreducing conditions and compared
with those performed under reducing conditions (Fig. 3).
While under reducing conditions, both HMAbs coprecipi-
tated E1, indicating that they recognize E1 and E2 com-
plexes; when immunoprecipitations were performed un-
der nonreducing conditions which prevent the disulfide
bonds stabilizing E1E2 complexes, slow migrating bands
were also detected on the top of the gels. The latter
FIG. 2. Plasmids used in the epitope mapping studies. (A) Representation of the HCV genomic domain coding for the viral nucleocapsid (C), the
glycoproteins E1 and E2, and the nonstructural proteins p7, NS2, and NS3 (Rice et al., 1996). Amino acid position of the proteolytic cleavage sites are
indicated. (B) Map position and amino acid boundaries of the sequences encoded by the different expression plasmids.
TABLE 2
Immune Reactivity of Patients’s Sera and of Purified Monoclonal Antibodies (HMAbs) against Truncated Domains of E2
HCV constructsa A B C D E pCIE2a pCIE2t pcDNA3
Patient 1b
serum 1 2 1 2 2 1 1 2
HMAb 503 2 2 2 2 2 2 1 2
Patient 2b
serum 2 2 2 2 2 2 1 2
HMAb 108 2 2 2 2 2 2 1 2
Mouse polyclonal Abc 1 1 1 1 1 1 1 2
a LTK cells were transiently transfected with the indicated plasmids and IFA performed 48 hrs later as described in Major et al., (Major et al., 1995).
The pS2.SE2A-E plasmids are according to Nakano et al., (Nakano et al., 1997). The pcDNA3 plasmid (Promega) was used as a negative control.
b Patients’ sera were tested at 1/20 dilution; supernatants of LCLs or purified HMAbs were used at a concentration up to 10 mg/ml in at least two
independently performed experiments.
c The efficiency of transfection and proper expression of the plasmids was evaluated in all cases using a reactive hyperimmune serum obtained
from mice immunized by direct injection of the plasmid pCIE2t (Nakano et al., 1997).
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observation suggests that the E1E2 complexes precipi-
tated consisted of noncovalently associated hetero-
dimers and heterogeneous linked aggregates. As previ-
ously observed, for MAb H2 which has been, shown
capable to recognize a native form of E2, only bands
corresponding to E1 and E2 were detected on the gel in
that case (Fig. 3, nonreducing, H2, Deleersnyder et al.,
1997). Under nonreducing conditions, the coprecipitation
of the E1 monomeric form with HMAb 108 was poorer
with a specific band detected only after a long exposure
time as compared with HMAb 503. Thus both HMAbs
recognize domain(s) of the E2 protein that appear folded
early and would stay accessible as the protein adopts its
final conformation as suggested by the coprecipitation of
noncovalently associated E1E2 complexes.
All together, our data indicate that both HMAbs 108
and 503 recognize a conformation-dependent determi-
nant (or determinants) and could precipitate E1 and E2
noncovalently associated complexes which are believed
to exist on the virion particle.
Neutralization of E2 binding onto cells
The assay recently developed by Rosa et al. (1996)
allows us to evaluate, in a quantitative fashion, the ability
of candidate antibodies to neutralize the binding of
highly purified E2 (neutralizing of binding or NOB) onto
cells susceptible to HCV infection. Both HMAbs were
evaluated in this assay. Percent neutralization obtained
at different concentrations of the antibodies are shown in
Fig. 4. Results indicate that the HMAb 503 displayed
NOB activity and that 50% neutralization of binding was
achieved at a concentration of 0.03 mg/ml. No NOB
activity could be detected for HMAb 108 at any of the
concentration tested. Thus one HMAb purified in our
study was capable of NOB activity. This is the first such
antibody described to date. Interestingly, the fact that the
producing clone (503) was derived from a genotype 4-in-
fected patient while the assay used a genotype 1(a)-
derived antigen confirms the cross-reactive potential of
this antibody. The data also suggest that antibodies with
NOB-activity seem to be targeted at determinants con-
served between different viral genotypes.
FIG. 4. Percent neutralization of E2 binding by HCV-E2 HMAbs.
Various concentrations of anti-E2 HMAbs 503 and 108 were tested for
their ability to neutralize binding of purified CHO-expressed E2 protein
onto MOLT-4 cells. Neutralization was calculated as described (Rosa et
al., 1996) and 50% neutralization titers are indicated.
FIG. 3. Immunoprecipitation of E2 and coprecipitation of E1 and
analysis of epitope formation under under reducing and nonreducing
conditions. Cells coinfected with vTF7–3 and vHCV1–1488 (vHCV) or
with TF7–3 alone (M) were pulse labeled for 5 min and chased for the
indicated times (in hours). The E2 glycoprotein was immunoprecipi-
tated with HMAbs 108, 503, and mouse MAbs H2 (Deleersnyder et al.,
1997) and A11 (Dubuisson et al., 1994). Immunoprecipitates were an-
alyzed under reducing or nonreducing conditions by SDS-PAGE (10%
acrylamide). Expected position of HCV-specific proteins are indicated
at the left of the figures.
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Competition experiments were performed to deter-
mine whether the two antibodies bind to similar or topo-
graphically distinct epitopes. The HMAb 108 did not
prevent (i.e., did not compete) the detection of the neu-
tralizing activity of the 503 Ab even when it was used at
the highest concentration (2.5 mg/ml, data not shown).
These results strongly suggest that the HMAbs 108 and
503 recognize different epitopes on the E2 protein.
DISCUSSION
Probing for the B-cell repertoire in viral infections is
critical for the understanding of pathogenesis associated
with these infections. Human monoclonal antibodies pro-
vide an alternative method to do so. Isolation and char-
acterization of such antibodies have been reported in the
case of HCV for only a limited number of viral antigens.
These include the nucleocapsid, the NS3 and NS4 pro-
teins (Cerino and Mondelli, 1991; Akatsuka et al., 1993;
Cerino et al., 1993; Mondelli et al., 1994; Chan et al., 1996)
and more recently the glycoprotein E2 (Chan et al., 1996).
In the latter case, authors used the phage display tech-
nology coupled with the use of synthetic peptides for the
screening of the anti-E2 immune reactivity and were able
to obtain specific IgG single-chain Fvs that recognized
the E2 sequence. While a specific linear epitope se-
quence was identified, no biological activity for the an-
ti-E2 antibody was described, and the putative role of this
antibody in the control or progression of infection re-
mains undefined.
We have focused the present study on the glycoprotein
E2 of HCV and selected a screening assay that specifi-
cally allows the detection of anti-E2 antibodies capable
of recognizing E2 directly expressed in cells without the
requirement of antigen purification. Such a screening
assay was chosen to enhance the chances of purifying
antibodies directed at conformation-dependent determi-
nants. The assay was also based on expression of a
genotype 1a-derived antigen, thus allowing for the char-
acterization of cross-reactive anti-E2 antibodies and
epitopes. Such reagents could be particularly useful for
the development of therapeutic or preventive strategies
to fight infection by a highly mutable agent such as HCV.
Using this approach, we have successfully derived two
clones producing anti-E2 antibodies from two HCV
chronically infected patients. The first clone (clone 503)
was obtained from one patient (Patient 1) infected by a
genotype 4 isolate while the second clone (clone 108)
was derived from a second patient (Patient 2) infected by
a genotype 1b isolate. We showed that the HMAbs dis-
played, in addition, a good reactivity against a genotype
1b antigen, suggesting that the determinant(s) targeted
by these antibodies is conserved among at least two of
the main prevalent viral subtypes found in the world
(subtypes 1a and 1b).
Our results indicate that the determinants recognized
by the HMAbs produced in our study are targeted at
conformation-dependent domains of E2. Indeed, we
failed to identify linear determinants using different
screening approaches, including peptide-scanning,
Western blots, and immunofluorescence analysis using
expressed truncated domains of the protein. On the other
hand, immunoprecipitation studies performed under re-
ducing or nonreducing conditions indicated that the
HMAbs recognized a conformation dependent-determi-
nant. Under nonreducing conditions, we showed that
these antibodies precipitated covalently as well as non-
covalently associated E1E2 complexes. The latter are
thought to be functional subunits incorporated in the
virion particle (Deleersnyder et al., 1997). The present
data, in particular obtained from kinetic analysis of
epitope formation strongly indicate that the two HMAbs
may recognize domains of the E2 protein that appear to
be folded early. Such domains would stay accessible as
the protein further matures, until it adopts its final con-
formation characteristic of the form of E2 susceptible to
be present on the surface of virions. The kinetic analysis,
together with the NOB data (i.e., one antibody, 503, dis-
playing NOB activity, the other one, 108, displaying no
NOB activity) also suggest that the two antibodies rec-
ognize different determinants. Alternatively, that affinity of
the antibodies for the E2 protein differs. Studies are
ongoing to try and identify such determinants.
The most encouraging result of our study was the
demonstration that one of the HMAbs displayed strong
NOB activity. Our observations together with those of
Rosa et al. (1996) indicate that the determinant(s) recog-
nized by NOB antibodies are likely directed at conforma-
tion-dependent domains of E2, domains that appear to
be conserved between different genotypes. Such do-
mains seem to be distinct from the hypervariable region
1 (HVR) that has been shown to contain neutralization
epitopes. In a recent study, Zibert et al. (1997) have been
able to correlate early appearance of antibodies directed
at a nonconformational structure found in the HVR with
acute self-limited infection. Results from the study sug-
gests the critical existence and role of antibodies di-
rected at a linear determinant of E2 in the control of HCV
infection, observations that are in agreement with a
study originally performed in the chimpanzee model by
Farci et al. (1996). Authors in this latter study generated
a hyperimmune serum directed at a peptide from the
HVR, a serum that contained antibodies capable of neu-
tralizing the infectivity of a well-characterized inoculum in
vitro. A similar experiment was also performed by
Shimizu et al. (1996). Thus all of these studies strongly
suggest that neutralization of HCV would mostly be type-
specific, involving the participation of variable, noncon-
served epitopes. Nonetheless, recent observations have
begun to suggest the existence of other neutralization
determinants, cross-reactive and not directed at the HVR.
In the vaccination study by Choo et al. (1994), induced
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neutralizing antibodies were not directed at the HVR of
E2 but apparently at other determinants carried by the
antigen. Abrignani has recently observed a correlation
between spontaneous resolution of chronic infection and
appearance of high anti-NOB antibody titers (Abrignani
1997). In patients described in this study, high or mea-
surable neutralization of binding of E2 was not restricted
to sera from patients infected with genotype 1a isolates,
thus suggesting the existence of cross-reactive epitopes
such as those described in our study. While it is difficult
to find a direct correlation between NOB titers of a
purified MAb and titers found in patients’ sera (both
patients in our study had similar NOB serum titers rang-
ing between 1:5000 and 1:6000), we can stress the fact
that antibody 503 has an NOB activity detectable at very
low concentration (0.03 mg/ml), suggesting a potent ac-
tivity.
The HMAbs produced in our study should be useful
tools to study further the biogenesis, folding, and assem-
bly of HCV glycoproteins as well as for characterization
of the virion structure and a putative cell-surface recep-
tor. As one of them (Ab 503) represents the first HMAb
described to date as having NOB activity, it would be also
of evident interest to determine the performances of this
antibody in passive immunization studies. Antibody infu-
sion studies have demonstrated, in the case of lentivi-
ruses, a beneficial role of administered neutralizing an-
tibodies in the control and even the prevention of infec-
tion in different animal models (Putkonen et al., 1991;
Emini et al., 1992; Conley et al., 1996).
MATERIALS AND METHODS
Patients
Two patients were enrolled in the study. HCV infection
was determined by the RIBA III assay (Abbott Laboratories).
At time of PBMC immortalization, both patients had chronic
hepatitis as determined by histological examination and
positive PCR assays. In one of these two patients, Patient 1,
despite detectable HCV RNA by PCR in the serum, serum
ALT (alanine amino transferase) levels were and remained
normal (mild hepatitis). In contrast, ALT levels remained
persistently elevated in Patient 2, and infection in this pa-
tient was characterized by cirrhosis.
Screening assay for the detection of anti-E2
antibodies
Detection of anti-E2 antibodies has been reported to
be tightly dependent on the antigen production method
(Chien et al., 1993; Hsu et al., 1993; Lesniewski et al.,
1995). Eukaryotic but not prokaryotic expression of HCV
E2 has been shown to allow for proper processing and
glycosylation of the protein (Selby et al., 1993). In our
study, we used as screening assay for anti-E2 antibodies
an eukaryotic-expressed E2 antigen analyzed under a
native form, i.e., visualized by an immunofluorescence
assay (IFA). Such a detection assay has been previously
used by Fournillier-Jacob et al. (1996b) and shown to be
particularly efficient for antibody detection. Briefly, a re-
combinant plasmid, pCW18 E2, expressing HCV E2
amino acid sequence 371–746 from the prototype strain
H (genotype 1a) was used to transfect CV-1 cells to-
gether with a helper SV40 mutant virus to generate the
stock of recombinant virus expressing E2 (SVE2,
Wychowski et al., 1986; Fournillier-Jacob et al., 1996a).
SVE2 virus was used to further infect CV-1 cells, and
immunofluorescence analysis were performed using
sera from infected patients and supernatants from EBV-
immortalized B cells as previously described (Fournillier-
Jacob et al., 1996b). Cells were fixed in methanol:acetone
(3:7) prior to analysis.
Generation of HMAbs producing cells lines
Generation of HMAbs producing cell lines was per-
formed as previously described (Seigneurin et al., 1983;
Desgranges et al., 1988; Boyer et al., 1991). Briefly, after
Ficoll isolation, PBMCs were exposed to EBV culture
supernatant (1 ml of B95.8 strain supernatant with a titer
of 1023 TD50/ml for 5 3 106 PBMCs) at room temperature.
After incubation, they were diluted in medium at concen-
tration ranging from 50 to 100 3 103 cells per well. After
2–4 weeks, the supernatants were screened for anti-E2
reactivity by the SVE2 CV-1 IFA. LCLs were further sub-
cloned twice at 2–20 cells per well with 50 3 103 irradi-
ated (2500 rads) allogenic PBMCs. Two persistently pos-
itive clones derived from the two patients were obtained.
Determination of viral load and genotype
Serum viral loads were determined using the bDNA
assay version 2.0 (quantiplex HCV RNA Assay, Chiron
Diagnostics). HCV genotypes were determined using
two different methods. The first method was based on
the detection of genotype-specific antibodies directed at
the nonstructural antigen 4 (NS4) and was determined
using the MUREX 1–6 serotyping assay according to the
manufacturer’s instruction (MUREX Diagnostics SA,
Bhattacherjee et al., 1995). The second one was based
on the amplification of viral sequences from the 59 non-
coding region (NCR) of the genome using genotype/
subtype specific primers and was performed using the
INNO-LIPA assay (Innogenetics S.A.).
Typing, purification, and determination of the
concentration of antibodies produced by the two
clones
Supernatants from each clone were tested by IFA on
CV-1 cells infected with the recombinant SVE2 virus, and
staining was revealed using specific secondary antibod-
ies for human IgM, IgG or IgA (Byosis), IgG1, IgG2, IgG3,
and IgG4 subclasses (Sigma Immuno Chemical Co.) and
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for l and k light chains (Dakopatts). A protein A (Phar-
macia) column was used for affinity purification of super-
natant producing HMAbs. The determination of antibody
concentration in culture supernatants was performed by
ELISA as previously described (Boyer et al., 1991).
Western blot analysis and peptide scanning
For Western blotting analysis, baculovirus-expressed
E2 proteins from a genotype 1a and 1b sequence were
used as previously described (Nakano et al., 1997). Pa-
tients’ sera (1:50), supernatants from the two clones, and
purified HMAbs (tested at a concentration as high as 10
mg/ml) were used. Epitope mapping using patient’s sera
as well as purified antibodies was performed using a
panoply of synthetic peptides covering the entire E2
open reading frame as previously described (courtesy of
A. M. Prince, Wang et al., 1996). The synthetic peptides
were mostly 12-mer with 6-aa overlap between succes-
sive peptides, corresponding to the sequences of HCV-H
strain (genotype 1a) E2 protein. There were a total of 57
peptides for E2 (aa 384–727), all of which were synthe-
sized by AnaSpec.
Epitope mapping
The two HMAbs obtained were evaluated for reactivity
by IFA on LTK cells transfected by a panoply of vectors
expressing truncated domains of the E2 protein (see Fig.
2). E2 sequences were cloned directly under the CMV
promoter of the pcDNA3 plasmid (Promega) for plasmids
pCIE2a and pCIE2t or expressed as fusion proteins with
the hepatitis B virus surface antigens for plasmids
pS2S.E2A-E using standard techniques and as previ-
ously described (Sambrook et al., 1989; Nakano et al.,
1997). All DNA preparations were generated using Qia-
gen purification columns (Qiagen) according to the man-
ufacturer’s instructions. LTK cells were transfected using
1.0 mg of DNA in presence of Lipofectamine (Gibco BRL).
The immune-reactivity of cell supernatants and of puri-
fied HMAbs were tested by IFA at 48 h postinfection as
previously described (Major et al., 1995). Positive control
included the use of a reactive hyperimmune serum gen-
erated from mice immunized by the direct injection of the
plasmid pCIE2t (Nakano et al., 1997). Negative controls
included the use of uninfected LTK cells as well as CV-1
cells infected with a recombinant SV40 virus expressing
E1 (Fournillier-Jacob et al., 1996a).
Metabolic labeling and immunoprecipitation
For the purpose of our study, different recombinant
viruses were used. These included (1) a recombinant
vaccinia virus vTF7.3 expressing the T7 DNA-dependent
RNA polymerase (Fuerst et al., 1986), (2) a panoply of
recombinant vaccinia viruses expressing HCV-H amino
acid sequences, vHCV 170–809, vHCV 371–809, vHCV
1–1488, and vHCV 370–661 (Grakoui et al., 1993; Major et
al., 1995; Fournillier-Jacob et al., 1996a; Michalak et al.,
1997), and (3) a recombinant Sindbis virus (Sinrep/HCV-
BK1–1207) expressing the structural proteins of a geno-
type 1b strain, the BK strain (Dubuisson et al., 1994). Viral
stocks were generated in CV-1 monolayers (for the vac-
cinia viruses) or in BHK-21 cells (for the Sindbis virus) as
described (Bredenbdeeck et al., 1993; Dubuisson et al.,
1994). Cells were infected and metabolically labeled with
35S-translabel (ICN) as previously described (Dubuisson
et al., 1994; Dubuisson and Rice, 1996). Cells were lysed
with 0.5% NP-40 in 10 mM Tris-HCl (ph 7.5), 150 mM
NaCl, and 2 mM EDTA Iodoacetamide (20 mM) was
included in the lysis buffer for experiments in which
disulfide bond formation was assayed. Immunoprecipi-
tations were carried out as described (Dubuisson et al.,
1994; Dubuisson and Rice, 1996). For quantitative exper-
iments, autoradiographs were analyzed by densitometry.
Neutralization assay
We assessed the ability of the HMAbs to neutralize the
binding (NOB) of E2 to MOLT 4 cells in the assay recently
developed by Rosa et al. (1996). The assay was run in 96
U-bottom microplates. Briefly, 20 ml of recombinant CHO
E2384–715 proteins at 0.5 mg/ml was mixed with various
dilution of anti-E2 HMAbs and control HMAbs (Boyer et
al., 1991; Rosa et al., 1996). After incubation at 4°C for 1 h,
the mixture was added to MOLT-4 cells (105 cells per
well). After washing, cells were subsequently incubated
with 1/100 dilution of human serum with anti-E2 immu-
noglobulins which recognizes E2 bound to target cells.
Cells were washed and incubated with fluoresceine iso-
thiocianate-conjugated antiserum to IgG. Fluorescence
was analyzed with a FACScan flow cytometer. Specific
neutralization was calculated as follow: [(positive control
MFI 2 experimental MFI)/(positive control MFI 2 nega-
tive control MFI)] 3 100 where (MFI) 5 mean fluores-
cence intensity of the cell population which directly re-
lates to the surface density of fluorescently labeled HCV
proteins bound to the cells. MFI values of cells incubated
with or without HCV proteins and with the HCV HMAbs
or HCV-negative HMAbs or pre-immune sera (Rosa et al.,
1996) are compared. The threshold of positivity is set for
each experiment by flow cytometric analysis of cells
without HCV proteins bound that have been incubated
with antisera to HCV proteins and the fluorescein iso-
thiocyanate-labeled second antibody. For competition
binding analysis, antibodies were biotinylated as fol-
lowed: 1 mg/ml of the antibodies in 0.4 M phosphate
buffer were incubated with N-N-dimethylformamide bi-
otin at 2 mg/ml at 4°C for 2 h and dialyzed extensively
against PBS overnight. Suboptimal concentration of bio-
tinylated HCV E2 1a was preincubated with different
amounts of unlabelled HMAbs 108 and 503 (20 min at
37°C); then, on ice were added 3 3 104 cells/well. After
30 min, samples were washed twice and streptavidin
39HMabs SPECIFIC TO HCV CHARACTERIZED
peroxydase conjugate was added; after 20 min on ice,
samples were read.
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